头孢吡普药敏检测方法比较:纸片扩散法、MIC试纸条法与微量肉汤稀释法
以微量肉汤稀释法为参考,评估MIC试纸条法与纸片扩散法对422株金黄色葡萄球菌临床分离株的头孢吡普药敏检测性能。MIC试纸条法与参考方法分类一致率达98.8%,纸片扩散法性能依赖折点标准:EUCAST下一致率89.6%,FDA下升至94.1%。
要点
- MIC试纸条法与微量肉汤稀释法高度一致,可作为常规药敏检测选项。
- 纸片扩散法在FDA折点下适用常规检测,EUCAST折点下MRSA ATU区需确认。
- 头孢吡普对金黄色葡萄球菌保持强效活性,总体敏感率98.8%。
核心结论
- MIC试纸条法检测头孢吡普对金黄色葡萄球菌的药敏性能可靠,纸片扩散法适用性取决于所用折点标准。
研究设计与样本
- 以微量肉汤稀释法为参考标准,对422株金黄色葡萄球菌临床分离株比较MIC试纸条法与纸片扩散法的检测性能。
主要发现
- 头孢吡普MIC₅₀/MIC₉₀为0.5/1 mg/L,总体敏感率98.8%,MRSA敏感率97.6%。
- MIC试纸条法在EUCAST标准下分类一致率98.8%,重大误差1.2%,极重大误差0。
- 纸片扩散法在EUCAST标准下总体一致率89.6%,重大误差10.6%,极重大误差0;FDA折点下一致率94.1%,重大误差1.7%。
- EUCAST定义的ATU区内MRSA占40.3%,参考微量肉汤稀释法均显示敏感。
关键数值与推荐
- MIC试纸条法结果满足ISO 20776-2:2021与CLSI M52的可接受限。
- EUCAST标准下MRSA落入ATU区者应以微量肉汤稀释法或MIC试纸条法确认。
- FDA折点下因无耐药株,极重大误差未确定。
临床怎么用
- 实验室可选用MIC试纸条法作为头孢吡普药敏常规检测方法。
- 使用FDA折点的实验室可采用纸片扩散法进行常规检测。
- 使用EUCAST标准的实验室遇MRSA纸片扩散法结果落入ATU区时,需用微量肉汤稀释法或MIC试纸条法确认。
局限性
- FDA折点下未评估极重大误差,因未检出耐药分离株。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Ceftobiprole is a new-generation cephalosporin with activity against Staphylococcus aureus, but a comprehensive evaluation of MIC Test Strip (MTS) and disk diffusion (DD) methods using EUCAST and FDA breakpoint is lacking. Using broth microdilution (BMD) as the reference standard, we assessed the performance of MTS and DD for determining ceftobiprole susceptibility among 422 clinical S. aureus isolates. Ceftobiprole retained potent activity, with MIC₅₀/MIC₉₀ of 0.5/1 mg/L and an overall susceptibility rate of 98.8%; methicillin-resistant Staphylococcus aureus (MRSA) showed 97.6% susceptibility. MTS demonstrated high agreement with BMD, achieving 98.8% categorical agreement (CA), 1.2% major error (ME), and zero very major error (VME) under European Committee on Antimicrobial Susceptibility Testing (EUCAST) criteria, meeting the acceptability limits of ISO 20776-2:2021 and CLSI M52. DD performance was breakpoint-dependent: under EUCAST criteria, the overall CA was 89.6%, with 10.6% ME and 0 VME. The 40.3% of MRSA that fell into the EUCAST-defined Area of Technical Uncertainty (ATU) zone were all shown to be susceptible by the reference BMD method. Under Food and Drug Administration (FDA) breakpoints, the CA rose to 94.1% and ME fell to 1.7%. Consequently, MTS offers a reliable routine option; DD is suitable for routine testing under FDA breakpoints, while for EUCAST users, MRSA isolates in the ATU zone should be confirmed by BMD or MTS. VME was not determined under FDA breakpoints due to the absence of resistant isolates. IMPORTANCE: Ceftobiprole offers a β-lactam option for Staphylococcus aureus, including methicillin-resistant Staphylococcus aureus (MRSA); however, its susceptibility testing remains insufficiently examined across both European Committee on Antimicrobial Susceptibility Testing (EUCAST) and Food and Drug Administration (FDA) interpretive criteria. We systematically compared MIC Test Strip (MTS) and disk diffusion (DD) with broth microdilution (BMD), demonstrating breakpoint-specific performance for methicillin-susceptible Staphylococcus aureus (MSSA) and MRSA and providing practical recommendations that allow laboratories to report accurate results regardless of the guidelines they follow.
引用
- Wang X, Tian Y, Jin Y, et al. Comparison of ceftobiprole 5 μg disk diffusion, MIC test strip, and broth microdilution for susceptibility testing of Staphylococcus aureus clinical isolates. J Clin Microbiol. 2026. PMID: 41870254. doi:10.1128/jcm.00125-26
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。